Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Melanoma

Neoplasm Metastasis

Melanoma, Cutaneous Malignant

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Intraocular Melanoma

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Analgesics

Melphalan

Liver Extracts

Antineoplastic Agents, Immunological

Interleukin-2

Antineoplastic Agents, Alkylating

Alkylating Agents

Immunosuppressive Agents

Immunologic Factors

Analgesics, Non-Narcotic

Autologous TIL administered via hepatic arterial infusion followed by low dose Interleukin-2 after preconditioning chemotherapy with Melphalan.

Administered via hepatic arterial infusion

Autologous Tumor Infiltrating Lymphocytes

Melphalan will be administered once as an intravenous infusion.

After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.

Lars Ny

Axel Nelson

The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases (including but not restricted to) of malignant melanoma.

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

Adverse events are graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

Evaluation of hepatic progression-free survival

Defined as the proportion of patients included that receive treatment with the TIL product.

Miltenyi Biomedicine GmbH

Vastra Gotaland Region

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases	NCT04812470	Metastatic Uvea... Metastatic Cuta...	Autologous Tumo... Melphalan Interleukin-2	18 Years -	Vastra Gotaland Region
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases	NCT04812470	Metastatic Uvea... Metastatic Cuta...	Autologous Tumo... Melphalan Interleukin-2	18 Years -	Vastra Gotaland Region

Spots Global Cancer Trial Database for bioreactor

Every month we try and update this database with for bioreactor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for bioreactor

Every month we try and update this database with for bioreactor cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for bioreactor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.